EUCTR2011-001739-21-IT
Active, not recruiting
Not Applicable
A study of Sativex for pain Relief and appetite stimulation in Patients with advanced malignancy. Phase II
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE0 sitesMarch 13, 2012
Conditionsadvanced malignant cancerMedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
Drugssativex
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- advanced malignant cancer
- Sponsor
- ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE G. PASCALE
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The patient has advanced active cancer for which there is no known curative therapy. • The patient is able (in the investigators opinion) and willing to comply with all study requirements. • The patient has a clinical diagnosis of cancer related pain, which is not wholly alleviated with their current opioid treatment. • The patient is receiving a sustained release (SR) fixed dose of opioid therapy (excluding Methadone). N.B. The opiate therapy must be Step III according to the WHO analgesic ladder. • The patient is willing to continue to take their regular daily baseline opioid regimen (SR) at the same dose, throughout the duration of study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range 98
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range 98
Exclusion Criteria
- •The patient should be excluded from entering study if they have received or are due to receive during the study period; chemotherapy, hormone therapy or radiotherapy, which, in the opinion of the investigator will affect their pain. • Any history or immediate family history of schizophrenia, other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with their underlying condition. • Any known or suspected history of a diagnosed dependence disorder, current heavy alcohol consumption, current use of an illicit drug or current non prescribed use of any prescription drug. • The patient has poorly controlled epilepsy or recurrent seizures (i.e. at least one year since last seizure). • The patient has experienced myocardial infarction or clinically relevant cardiac dysfunction within the last 12 months or has a cardiac disorder that, in the opinion of the investigator would put the patient at risk of a clinically relevant arrhythmia or myocardial infarction.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Effect of Sativex on pain and spasticity following spinal cord injuryEUCTR2012-005328-14-DKSpinal Cord Injury Centre of Western Denmark
Completed
Not Applicable
Study of analgesic and sedative effects of suppository yokukansan for pediatric patient with postoperative tonsillectomyPediatric patient with tonsillectomyJPRN-UMIN000013938issay Hospital20
Recruiting
Not Applicable
A study on the effectiveness of analgesics in patients undergoing thyroidectomyKCT0008131The Catholic University of Korea, Seoul St. Mary's Hospital62
Completed
Not Applicable
sing of the absorbable scaffold containing slow releasing lidocaine in surgery area.Impacted teeth.An impacted tooth is a tooth that has failed to erupt because of obstruction by another tooth.IRCT201705063018N3Research Vice-chancellor Tabriz Univercity of Medical Sciences72
Active, not recruiting
Phase 1
SATIVEX® AS ADD-ON THERAPY VS. FURTHER OPTIMIZED FIRST-LINE ANTISPASTICSModerate to severe spasticity due to MS (multiple sclerosis).MedDRA version: 19.0Level: HLTClassification code 10052785Term: Multiple sclerosis acute and progressiveSystem Organ Class: 100000004852Therapeutic area: Diseases [C] - Nervous System Diseases [C10]EUCTR2015-004451-40-CZAlmirall Hermal GmbH228